Skip to content

Synerkine Pharma appoints industry veteran Anders Ekblom to its Board of Directors

Leiden, The Netherlands – January 25, 2024

Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, today announced the appointment of industry veteran Anders Ekblom, MD, PhD, DDS as a new Member of its Board of Directors. The appointment of Dr. Ekblom adds a wealth of pharmaceutical industry and drug development expertise to Synerkine Pharma’s board combined with his scientific knowledge of pain physiology and the implications of pain in various disease settings and markets.

Dr. Ekblom spent two decades at AstraZeneca, as a member of global executive teams including roles as Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and CEO of AstraZeneca AB Sweden. He has previously been Chairman of the Board of the Karolinska University Hospital and board member of the Swedish Research Council. Dr. Ekblom recently joined Flerie’s Board of Directors, and currently also serves as Chairman of the Board of Directors and Board Member for several biopharmaceutical start-ups. Anders Ekblom is a board-certified MD in Anesthesiology and Intensive Care, PhD, Doctor of Dental Surgery, and serves as an Associate Professor at the Karolinska Institute in Sweden.

“I am looking forward to working with Anders who brings a rich set of complementary strengths and expertise to our Board. His deep understanding of the drug development process from one of the world-leading pharma companies and his existing networks in the industry make him a valuable addition to the Synerkine Pharma leadership group,” commented Hans Preusting, PhD, Chief Executive Officer of Synerkine Pharma.

Commenting on his appointment, Anders Ekblom added: “I am looking forward to contributing to the continued transformation of Synerkine Pharma into a clinical-stage biopharmaceutical company. As emphasized by the continued fallout of the opioid crisis in the United States, the pain market is clearly in need of innovation in the form of non-addictive, pain-resolving and not just suppressing treatment options. Synerkines represent a novel first-in-class approach to achieve such disease-modifying effect in chronic pain and potentially other clinical manifestations of pain.”

About Synerkine Pharma
Synerkine Pharma B.V. focuses on the development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.


For more information, please contact:


Hans Preusting

Chief Executive Officer


Media Relations

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951